Fig. 3.
Current progression-free survival.
Comparison of current progression-free survival between patients eligible to receive CD6 T-cell–depleted BMT and CD4+ DLI and a cohort of patients treated previously with CD6 BMT alone.
Current progression-free survival.
Comparison of current progression-free survival between patients eligible to receive CD6 T-cell–depleted BMT and CD4+ DLI and a cohort of patients treated previously with CD6 BMT alone.
